Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. CTMX
stocks logo

CTMX

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q3
FY2025Q4
FY2026Q1
7.51M
-80.27%
-0.050
-170.84%
6.67M
-86.91%
-0.083
-136.17%
14.79M
-20.73%
-0.100
-137.04%
Estimates Revision
The market is revising Downward the revenue expectations for CytomX Therapeutics, Inc. (CTMX) for FY2025, with the revenue forecasts being adjusted by -10.59% over the past three months. During the same period, the stock price has changed by 109.50%.
Revenue Estimates for FY2025
Revise Downward
down Image
-10.59%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-178.02%
In Past 3 Month
Stock Price
Go Up
up Image
+109.50%
In Past 3 Month
Wall Street analysts forecast CTMX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CTMX is 6.50 USD with a low forecast of 3.50 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Analyst Rating
Wall Street analysts forecast CTMX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CTMX is 6.50 USD with a low forecast of 3.50 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Buy
1 Hold
0 Sell
Strong Buy
Current: 4.190
sliders
Low
3.50
Averages
6.50
High
10.00
Current: 4.190
sliders
Low
3.50
Averages
6.50
High
10.00
H.C. Wainwright
Mitchell Kapoor
Buy
maintain
$5 -> $10
2025-11-11
Reason
H.C. Wainwright
Mitchell Kapoor
Price Target
$5 -> $10
2025-11-11
maintain
Buy
Reason
H.C. Wainwright analyst Mitchell Kapoor raised the firm's price target on CytomX Therapeutics to $10 from $5 and keeps a Buy rating on the shares. The firm says "strong" CX-2051 trial demand and expansion of enrollment to 100 patients should provide a stronger signal for an approval path.
Piper Sandler
NULL -> Overweight
maintain
$5
2025-11-10
Reason
Piper Sandler
Price Target
$5
2025-11-10
maintain
NULL -> Overweight
Reason
Piper Sandler raised the firm's price target on CytomX Therapeutics to $6.50 from $5 and keeps an Overweight rating on the shares. At SITC, CytomX presented Phase I data on Probody masked IFNalpha2b CX-801 in melanoma and preclinical data on Probody CDH3 T-cell engager CX-908. CytomX will present Phase I CX-801 data in combination with KEYTRUDA in advanced melanoma patients next year. Initial Phase I data on Probody masked EpCAM ADC CX-2051 showed doses of 7.2-10mg/kg achieved an impressive 28% ORR, 94% DCR and preliminary mPFS of 5.8 months in 3rd-line+ metastatic colorectal cancer.
Barclays
Etzer Darout
maintain
$6
2025-10-21
Reason
Barclays
Etzer Darout
Price Target
$6
2025-10-21
maintain
Reason
Barclays analyst Etzer Darout raised the firm's price target on CytomX Therapeutics to $6 from $3.50 and keeps an Overweight rating on the shares. The company's data in late-line colorectal cancer compares favorably to peers, the analyst tells investors in a research note.
Cantor Fitzgerald
NULL -> Overweight
initiated
$6
2025-09-22
Reason
Cantor Fitzgerald
Price Target
$6
2025-09-22
initiated
NULL -> Overweight
Reason
Cantor Fitzgerald initiated coverage of CytomX Therapeutics with an Overweight rating and $6 price target.
Cantor Fitzgerald
Overweight
initiated
$6
2025-09-22
Reason
Cantor Fitzgerald
Price Target
$6
2025-09-22
initiated
Overweight
Reason
Cantor Fitzgerald initiated coverage of CytomX Therapeutics with an Overweight rating and $6 price target. CytomX may have a real contender on its hands with CX-051, a masked epithelial cell adhesion molecule antibody-drug conjugate, and one it can build a franchise around, the analyst tells investors in a research note. Cantor likes the setup, saying that if CX-2051 delivers, CytomX owns a first-in-class space with blockbuster potential in colorectal cancer, and optionality well beyond that.
Barclays
initiated
$3.50
2025-09-16
Reason
Barclays
Price Target
$3.50
2025-09-16
initiated
Reason
Barclays initiated coverage of CytomX Therapeutics with an Overweight rating and $3.50 price target.
See All Ratings

Valuation Metrics

The current forward P/E ratio for CytomX Therapeutics Inc (CTMX.O) is -11.24, compared to its 5-year average forward P/E of 13.16. For a more detailed relative valuation and DCF analysis to assess CytomX Therapeutics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
13.16
Current PE
-11.24
Overvalued PE
83.89
Undervalued PE
-57.57

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-0.59
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
10.56
Undervalued EV/EBITDA
-11.75

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
3.54
Current PS
0.00
Overvalued PS
7.32
Undervalued PS
-0.24
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders areSelling! The selling amount has increased 359.35% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 1979% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areSelling! The selling amount has increased 359.35% over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

CTMX News & Events

Events Timeline

(ET)
2025-11-06
17:09:56
CytomX Therapeutics Announces Q3 Earnings Per Share of 9 Cents, Exceeding Consensus Estimate of 4 Cents
select
2025-10-20 (ET)
2025-10-20
16:38:38
CytomX Therapeutics names Rachael Lester as chief business officer
select
2025-10-14 (ET)
2025-10-14
12:12:36
Oppenheimer Optimistic About CytomX Following Merus Colon Cancer Results
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
6.5
11-22Yahoo Finance
Analysts Discuss the Evolving CytomX Narrative Following Recent Clinical Progress and Increased Price Target

  • Analyst Price Target Increase: CytomX Therapeutics' consensus analyst price target has risen from $6.14 to $7.07 per share, driven by positive clinical developments for its lead asset, CX-2051, in the colorectal cancer market.

  • Positive Analyst Sentiment: Analysts from firms like Oppenheimer and Cantor Fitzgerald have expressed bullish views on CytomX, highlighting the potential of CX-2051 and its strategic positioning, while Barclays remains more cautious with a lower price target.

  • Financial Stability and Future Projections: The company is noted for its strengthened financial position, with a cash runway expected to support operations through key clinical milestones in 2026, despite some concerns about the complexity of the colorectal cancer market.

  • Upcoming Data Presentation: CytomX is set to present initial data from its Phase 1 study of CX-801 for advanced melanoma at an upcoming conference, which could provide further insights into its early-stage pipeline and scientific approach.

[object Object]
Preview
4.0
11-11Benzinga
HC Wainwright & Co. Reaffirms Buy Rating for CytomX Therapeutics and Increases Price Target to $10
  • Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders to stay updated on market movements.
  • Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters for its users.
  • Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, enhancing their trading strategies.
  • Market Winning Tools: The service is designed to help traders win in the markets every day with accurate stock market intelligence.
[object Object]
Preview
9.0
11-07SeekingAlpha
CytomX announces Q1 2026 data update for CX-2051 and achieves 100-patient enrollment milestone as Phase Ib study progresses.

  • Management Updates: CytomX Therapeutics appointed Rachael Lester as Chief Business Officer to enhance strategic planning and business development, while CEO Sean McCarthy highlighted the promising interim Phase I data for CX-2051, targeting colorectal cancer with a potential new standard of care.

  • Clinical Development Plans: The company plans to expand the Phase I study of CX-2051 to about 100 patients by Q1 2026 and initiate a Phase Ib study with bevacizumab, alongside updates on additional indications for CX-2051 and CX-801-KEYTRUDA combination data expected in 2026.

  • Financial Performance: CytomX reported a significant revenue drop to $6 million in Q3 2025, down from $33.4 million in the previous year, primarily due to completed collaboration obligations, while maintaining a cash balance sufficient to fund operations through at least Q2 2027.

  • Analyst Sentiment and Risks: Analysts expressed optimism regarding the progress of CX-2051 and the company's pipeline, although concerns were raised about managing gastrointestinal adverse events and the need for a clear regulatory strategy as the dataset matures.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is CytomX Therapeutics Inc (CTMX) stock price today?

The current price of CTMX is 4.19 USD — it has increased 3.2 % in the last trading day.

arrow icon

What is CytomX Therapeutics Inc (CTMX)'s business?

CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The Company is focused on developing conditionally activated, masked biologics designed to be localized to the tumor microenvironment. The Company is developing a pipeline of localized biologics, through its PROBODY therapeutic platform. Its pipeline comprises therapeutic candidates across multiple treatment modalities, including ADCs, T-cell engagers, and immune modulators such as cytokines. Its clinical-stage pipeline includes CX-2051, CX-904 and CX-801. CX-2051 is a masked, conditionally activated ADC directed toward EpCAM, armed with a topoisomerase-1 inhibitor payload. CX-904 is a masked, conditionally activated T-cell-engaging bispecific antibody targeting the EGFR on tumor cells and the CD3 receptor on T cells. CX-801 is a masked interferon alpha-2b PROBODY cytokine with broad potential applicability in traditionally immuno-oncology-sensitive as well as insensitive (cold) tumors.

arrow icon

What is the price predicton of CTMX Stock?

Wall Street analysts forecast CTMX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CTMX is 6.50 USD with a low forecast of 3.50 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is CytomX Therapeutics Inc (CTMX)'s revenue for the last quarter?

CytomX Therapeutics Inc revenue for the last quarter amounts to 5.96M USD, decreased -82.16 % YoY.

arrow icon

What is CytomX Therapeutics Inc (CTMX)'s earnings per share (EPS) for the last quarter?

CytomX Therapeutics Inc. EPS for the last quarter amounts to -0.09 USD, decreased -228.57 % YoY.

arrow icon

What changes have occurred in the market's expectations for CytomX Therapeutics Inc (CTMX)'s fundamentals?

The market is revising Downward the revenue expectations for CytomX Therapeutics, Inc. (CTMX) for FY2025, with the revenue forecasts being adjusted by -10.59% over the past three months. During the same period, the stock price has changed by 109.50%.
arrow icon

How many employees does CytomX Therapeutics Inc (CTMX). have?

CytomX Therapeutics Inc (CTMX) has 119 emplpoyees as of December 13 2025.

arrow icon

What is CytomX Therapeutics Inc (CTMX) market cap?

Today CTMX has the market capitalization of 709.93M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free